Percutaneous transluminal renal artery stenting (PTRAS) is associated with declining renal function in a non-negligible portion of patients and is inflicted by different mechanisms, including atheroembolism. This study investigated whether delicate PTRAS to reduce atheroembolism might minimize postoperative renal injury and better preserve renal function. Patients undergoing PTRAS performed by experienced interventional cardiologists, applying coronary intervention concepts, techniques, devices and delicacy principles whenever possible, were prospectively studied. A total of 34 patients (29 M/5 F) with impaired renal function (group A, creatinine 2.4 ± 0.1 mg/dL) and another 20 patients (16 M/4 F) with normal serum creatinine (group B, baseline creatinine 1.2 ± 0.0 mg/dL) were studied. PTRAS was successfully performed in all but one group A patient. During a 6-month follow-up, systolic and diastolic blood pressure (130 ± 2 versus 148 ± 4 mmHg, P = 0.001 and 70 ± 2 versus 78 ± 3 mmHg, P = 0.006) and serum creatinine (2.1 ± 0.1 versus 2.4 ± 0.1 mg/dL, P < 0.001) were all significantly lowered in group A patients. Using a 20% change cut-off value, renal function improved in eight (24%), remained unchanged in 24 patients (73%), and deteriorated in only one patient (3%). The corresponding alterations in blood pressure and renal function were insignificant in group B patients. Patients with bilateral involvement (eleven patients) also had significantly lowered serum creatinine on follow-up. In conclusion, delicately practiced PTRAS can reduce the rate of postprocedural renal deterioration in patients with impaired renal function, and should be adopted in every renal intervention. ( 
ated with deteriorating renal function and worsening hypertension in a non-negligible portion of patients. 4, 5) Contrast-induced nephropathy (CIN) and distal renal atheroembolism are recognized as two major procedure-related causes of such complications, [6] [7] [8] especially in patients with existing renal insufficiency. As more knowledge is accumulating, the issue of CIN has been reduced to a certain extent. [9] [10] [11] Distal protection devices have been reported to reduce major events in coronary or carotid interventions, 12, 13) and protected renal interventions are showing promise. 14, 15) Thus, atheroembolism to distal renal beds could be an important issue, especially in long critical lesions with voluminous atheroma load. Inappropriate device manipulations and unnecessary forces may be blamed for inviting dislodgement of atheroma fragments.
The aim of this study was to explore whether delicate PTRAS, performed by experienced interventional cardiologists familiar with this procedure, applying percutaneous coronary intervention (PCI) concepts, techniques and devices, and least-traumatic manipulations whenever possible to reduce distal atheroembolism, may minimize the incidence of postoperative renal injury and improve the long-term clinical outcome of PTRAS, especially in patients with severe atherosclerotic renal artery stenosis and impaired renal function.
METHODS

Study population:
All patients who were primarily admitted for percutaneous renal artery interventions and those in whom severe renal artery stenosis was documented and treated during admission for coronary or peripheral interventions were prospectively studied beginning in June 2001. Patients with relevant clinical presentations, significant renal artery stenosis (≥ 70% diameter stenotic), and suitable for PTRAS were included. Coronary angiography was performed unless contraindicated or the coronary risk was minimal, and the number of vessels with ≥ 50% lumen stenosis was counted. All patients were clinically optimized before the procedure to reduce the risk of CIN (adequate hydration, no diuretics or nephrotoxic agents) and premedicated or loaded with dual antiplatelet agents (aspirin plus ticlopidine or clopidogrel). The angiography conducted should have used a minimal amount of low-osmolality contrast medium and the least number of injections possible. Patients were excluded from the study if they were receiving second-session PTRAS and the first-session attempt failed recently or more than 200 mL of contrast medium was administered for other causes within three days of the index intervention. Patients were also excluded if the lesion was less than 70% stenotic or there were signs of renal irreversibility (serum creatinine ≥ 4.0 mg/dL, renal size less than 7 cm in length, no late-phase nephrogram, severely impaired cortical blood flow or seriously abnormal intrarenal arteries). 16 performed by an inexperienced operator or improvisational intervention not complying with delicacy principles was also rejected. Group A consisted of patients with abnormal baseline serum creatinine (≥ 1.6 mg/dL), whereas patients with normal baseline serum creatinine (≤ 1.5 mg/dL) constituted group B. Creatinine clearance (CCr) was estimated by the Cockcroft-Gault (C-G) formula (CCr = (140-age in years) × weight in kilograms × 0.85 in females/serum creatinine in mg/dL × 72). 17) This study protocol was approved by the institutional review board and all participants gave their informed consent. Delicate PTRAS: PTRAS should be performed by qualified interventional cardiologists well experienced in PCI and familiar with PTRAS. Delicate PTRAS implies application of the PCI concept, techniques and devices, minimal device manipulation, minimal damage to vessel walls, and no violent force during the procedure whenever possible to minimize intimal trauma or potential atheroembolism, both in the predilatation and stenting stages, especially in tight lesions with voluminous atheroma load. The number of predilatations should be minimized and direct stenting should be performed if no infliction of distal atheroembolisms is expected. All of these interventions were carried out without distal protection devices.
The standard femoral approach was used and 10,000 IU of unfractionated heparin was given before intervention. Soft-tipped renal guide catheters were used to engage the renal arterial ostium. Deep seating of or traversing the atheroma by the guide catheter was prohibited. Coronary wires (diameter, 0.014") and small coronary balloons were used for predilatation of very tight ostial lesions. Maneuvering of stiffer wires was performed gently, especially when crossing the lesions, and was kept to a minimum. Scaffolding the entire lesion, including the renal ostium, with stents was intended in every single case and performed by gently advancing the stent to or through the lesion and deploying the stent after precise positioning. The stents should match but never oversize the reference vessels to avoid edge dissection and were deployed with nominal pressures unless mandated. Only PTRAS was allowed in a single session unless the associated nonrenal intervention was indispensable. After the procedure, the patient was sent to the coronary care unit for close monitoring. The femoral access was closed with an auto-suture device at the catheterization lab or manually. Follow-up: Patients were released from the hospital one or two days after the interventions and followed-up first at an outpatient clinic two weeks later and then monthly thereafter. The stabilized serum creatinine 3 to 12 months after the procedure was collected as the follow-up renal function. Those with a ≥ 20% rise above the normal range in the follow-up serum creatinine were classified as having deteriorating renal function. Patients with abnormal baseline serum creatinine and a ≥ 20% decrease in follow-up serum creatinine were classified as having improving renal function. Those in between were classified as having stationary renal function. Statistics: All continuous variables are expressed as the mean ± SEM. Betweengroup and within-group differences in means were analyzed by unpaired and paired Student's t-test, respectively. Differences in categorical variables were measured by the chi-square test with Yate's correction. All statistical analyses were performed using SPSS for Windows, release 10.0.1 (SPSS Inc., Chicago, USA). A two-tailed P value < 0.05 was considered statistically significant. Table I . Patients in group A were significantly older (73 ± 1 versus 67 ± 2 years, P = 0.026) than, but otherwise indifferent from those in group B. In group A, 19 (56%) patients primarily had unexplained or progressive azotemia, 18 (53%) resistant hypertension, 8 (24%) angina, and 4 (13%) worsening heart failure. In group B, 18 (90%) patients had high or resistant hypertension, 5 (25%) angina, and 6 (30%) heart failure (pulmonary edema in two). The groups did not differ in the incidences of coronary or major peripheral arterial (extracranial four vessels, aorto-iliac and femoro-popliteal vessels) diseases. Nine (26%) patients in group A and 3 (15%) patients in group B had bilateral renal artery involvement. The numbers and classes of prescribed antihypertensive agents, including ACE inhibitors and ARB, before and after PTRAS in patients with bilateral renal artery stenoses were not different between the two groups. Two patients (6%) in group A had a functional solitary kidney as the contralateral renal arteries were totally occluded. One contralateral vessel was 65% stenotic and left untreated. One other nearly occluded contralateral renal artery could not be engaged due to anomalous origin despite prolonged procedure. Therefore, a total of 62 renal vessels were treated. 
RESULTS
Characteristics of renal artery stenoses and results of PTRAS:
The angiographic characteristics of the renal artery stenoses and PTRAS results in both groups are shown in Table II . The vessels were equally sized and the lesions similarly advanced and located in both groups. Twenty-five of 39 (64%) stenoses in group A and 12 of 23 (52%) in group B (P = NS) were predilated with smaller balloons due to very tight ostial lesions. The wires, balloon size, and inflation pressure used for predilatation were not different between the two groups. Smaller (0.018 or 0.014 inches) wires for stent deployment were used more frequently in group A. However, the stent sizes and final balloon pressure used were similar in both groups. The implanted stents included Intrastent Doublestrut and Paramount (Intratherapeutics, St. Paul, MN, USA), Palmaz Corinthian IQ, Genesis, and BX Velocity (Cordis Europa N.V., Roden, Netherlands), and Bridge X3 (Applied Vascular Engineering, Santa Rosa, CA, USA). There was no between-group difference in the makes of stents used. The residual stenosis in both groups was negligible and normal poststenting blood flow was achieved in all. Patients were discharged after a mean hospitalization of 3.6 ± 0.5 and 2.5 ± 0.4 days, respectively (P = NS). The numbers of associated coronary and peripheral interventions were not different between the two groups. Clinical follow-up: One group A patient who had functional solitary kidney and anomalous origin of renal artery died of acute renal failure 3 days after the procedure due to constrast overdose and thus could not complete the clinical follow-up. The follow-up blood pressure and renal function values obtained at a mean of 6.0 ± 0.6 and 5.8 ± 0.7 months, respectively after PTRAS are presented in Table III . Blood pressure in group A patients was significantly lower postintervention (systolic BP 130 ± 2 versus 148 ± 4 mmHg, P = 0.001; diastolic BP 70 ± 2 versus 78 ± 3 mmHg, P = 0.006), while in group B patients it was not significantly altered by the operation. Overall renal function improved significantly in group A patients (serum creatinine 2.1 ± 0.1 versus 2.4 ± 0.1 mg/dL, P < 0.001, Table III and Figure; estimated CCr 29 ± 2 versus 26 ± 2 mL/min, P = 0.002), with an improvement in 8 (24%) and no change in another 24 (73%) using a 20% change cut-off point. Only 1 (3%) of the patients who completed the clinical follow-up sustained deteriorated renal function. The serum creatinine level had not changed significantly at follow-up in group B patients. Using the 20% change cut-off point, 2 (10%) patients in group B sustained deterioration in renal function, whereas in the other 90% it remained unchanged. Among the two deteriorating patients, early in the case series an 81-year old male patient exhibited a nearly occluded stent on a follow-up angiogram because he did not receive dual antiplatelet agents after being discharged. His blood pressure remained high and renal function poor despite repeat PTAs. Subgroup analysis revealed these renal outcomes were independent of hypertension duration (< 5 years versus ≥ 5 years), renal insufficiency as primary presentation, severity of renal artery stenosis (< 90% versus ≥ 90%), balloon predilatation (direct stenting or not), or concurrent percutaneous interventions (PCI and PTA).
Patients with bilateral renal arterial involvement (N = 11) did not differ in baseline systolic blood pressure (145 ± 6 versus 147 ± 4 mmHg, P = NS), serum creatinine (2.1 ± 0.2 versus 1.9 ± 0.1 mg/dL, P = NS), estimated CCr (28 ± 3 versus 38 ± 3 mL/min, P = 0.087) or number of antihypertensives (2.4 ± 0.4 versus 2.9 ± 0.2, P = NS) from those with unilateral stenoses (N = 42) except having lower baseline diastolic blood pressure (69 ± 2 versus 80 ± 2 mmHg, P = 0.019). Among patients with bilateral renal artery stenoses, renal function improved significantly (serum creatinine 1.8 ± 0.2 versus 2.1 ± 0.2 mg/dL, P = 0.013; and estimated CCr 33 ± 3 versus 28 ± 3 mL/min, P = 0.001) and systolic blood pressure was significantly lowered (131 ± 5 versus 145 ± 7 mmHg, P = 0.025) at followup. Renal function improved in 2 (19%) and remained unchanged in 9 (81%) and no one who completed follow-up suffered from a decline in renal function. For patients with only unilateral involvement, neither serum creatinine (1.9 ± 0.1 versus 1.9 ± 0.1 mg/dL, P = 0.417) nor CCr (38 ± 3 versus 38 ± 3 mL/min, P = NS) had changed significantly 6 months after PTRAS, but their blood pressure was significantly lower (systolic BP130 ± 3 versus 147 ± 4 mmHg, P = 0.002; diastolic BP71 ± 2 versus 80 ± 2 mmHg, P = 0.025) despite similar antihypertensive use.
DISCUSSION
In this study, we obtained remarkable PTRAS results in patients with impaired renal function by complying with simple rules while using currently available devices and techniques. In brief, delicate PTRAS significantly lowered systolic and diastolic blood pressure and serum creatinine during a 6 month follow-up in patients with significant renal stenoses and a mean serum creatinine of 2.4 mg/dL. The trichotomized post-PTRAS renal function remained unchanged in most patients, improved in others, and deteriorated only rarely (3%-9%, depending on the cut-off point). The percentage of patients exhibiting postoperative renal deterioration compared very favorably with those reported in the literature (Table IV) . 2, 3, [18] [19] [20] [21] [22] [23] [24] [25] Benefits and complications of PTRAS: The benefits of renal stenting are demonstrated (Table IV) 2,3, [18] [19] [20] [21] [22] [23] [24] [25] by showing long-term improvement or stabilization of renal function and preservation of renal size, 26, 27) especially in patients with background renal dysfunction or bilateral arterial involvement. 20, 28) In most of the reports, post-PTRAS blood pressure was either controlled or restored to normal. These positive effects have also been demonstrated in patients with a single functioning kidney and even in patients requiring hemodialysis. 29, 30) The long-term survival of patients undergoing renal arterial intervention is good, but influenced Vol 46 No 6 greatly by renal function. 27) Though PTRAS is a simple and straightforward concept and procedure, complications do occur. 31 ) Some 25 to 30 percent of patients did sustain deterioration in renal function after intervention. 2, 4, 5) The percentage is quite consistent across different reports, although better results have been reported. 19, 32) Worsening of blood pressure also occurs after the procedure. 4, 5) Only if these formidable complications can be reasonably reduced will widespread adoption of PTRAS become more rational and persuading. The procedure-related causes of decline in renal function include distal atheroembolization to renal beds, CIN, and other iatrogenic complications in the catheterization lab. [6] [7] [8] Exposure of glomeruli to high perfusion pressure after angioplasty, adverse renal effects of medications, lesion recurrence, and the natural history of background renal diseases constitute the other causes. The procedure-related risk factors are, to some extent, controllable and should be carefully handled before and during the interventions. The importance of limiting radiocontrast use in PTRAS can not be overemphasized and was illustrated by one of our cases in whom prolonged and fruitless maneuvering due to anomalous renal artery origin resulted in contrast overdose and subsequent death. Renal atheroembolism and delicate PTRAS: Distal renal atheroembolism by PTRAS may be a crucial issue in patients with voluminous atheroma load and friable intima or in a protracted procedure, but is not often well appreciated. [33] [34] [35] This complication may occur microscopically or grossly, but is probably underrecognized due to large renal reserve. Guiding catheter intubation, primary stenting in the presence of very tight or friable atheroma, unnecessary balloon infla- tions before stenting, especially with large balloons and stiff wires, over-sized stents and high-pressure dilatation, unnecessary device manipulations and violent forces are all possible causes of distal embolism in PTRAS. Thus, special care should be exerted to avoid distal atheroembolism at every single step. These were the rationales on which our study design was based. Distal protection devices should have a role in renal interventions and some authors have reported promising early results. 14, 15, 36) Unfortunately, bulky device sizes, short renal artery length, early bifurcation, an acute angle from the abdominal aorta, and multiple branches make renal protection still a challenging job. Further refinement of these devices is warranted in the near future. At this moment of nonprotected renal interventions, all possible measures should be adopted to minimize atheroembolism, and thus postoperative renal deterioration, and promote better renal recovery. In this study, we have demonstrated that by simply complying with delicacy principles and concepts, excellent PTRAS results could be obtained by interventional cardiologists using currently available techniques and devices. Study limitations: The ideal way to report changes in renal function after PTRAS has not been definitively defined. In this study, we presented results using both 20%-change and 10%-change cutoff points. Either way, the renal outcomes were better than generally reported. Secondly, the volume of radiocontrast used in this study was not measured. However, the volume of contrast medium to be used in an individual study is hard to predict and should be left to the operators for tight control. In our patients, the principles of the lowest possible volume of lowosmolar contrast and fewest injections were followed, except in the only patient with a nearly occluded contralateral renal artery with anomalous origin in whom prolonged, desperate attempts resulted in an irreversible consequence. Conclusion: Well-practiced PTRAS, using currently available devices, performed by experienced interventional cardiologists could effectively reduce the chance of postoperative renal deterioration in patients with severe atherosclerotic renal artery stenosis and impaired renal function, and should be considered in every renal intervention without distal protection. Interventionists also need not be intimidated by bilateral renal arterial involvement or a stenotic single functioning kidney.
